PubMed HealthSearch

PubMed · 7914030

[Hepatic coma].

Abstract

The term "hepatic encephalopathy" describes the neuropsychiatric signs and symptoms of patients with acute or chronic liver disease, irrespective of the presence or absence of liver cirrhosis. Cerebral edema, the pathophysiology and treatment of which being quite different from hepatic encephalopathy, is the leading cause of death in patients with acute liver failure. Lactulose (orally or as enema) is one of the cornerstones of the treatment of hepatic encephalopathy; most important for the management of patients with cerebral edema is close monitoring (including intracranial pressure monitoring) of the patients and rapid reduction of intracranial pressure (e.g. with mannitol). The pathophysiologic and therapeutic concepts in the care of patients with hepatic encephalopathy and cerebral edema are described.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

E Walter. 1994-07-02. [Hepatic coma].. https://pubmed.ncbi.nlm.nih.gov/7914030/

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

Protective effects of liver-derived apolipoprotein A1 against heat stress-induced hypothalamic lipid metabolism and blood-brain barrier integrity.

Heat stress (HS), a prevalent occupational and environmental hazard, has increasingly been recognized as a major contributor to multiple physiological disorders. The hypothalamus, a key regulator of thermoregulation and endocrine signaling, is especially susceptible to metabolic and inflammatory disturbances induced by HS. This study investigates the interplay among lipid metabolism, blood-brain barrier (BBB) integrity, and neuroinflammation in the hypothalamus under HS conditions, with a specific focus on apolipoprotein A1 (APOA1) as a potential protective factor. To achieve this, we integrated proteomic and lipidomic analyses with experimental validation in porcine and murine models. Proteomic analysis identified 266 differentially expressed proteins (DEPs) in the hypothalamus following HS, with significant enrichment in lipid metabolism pathways-especially glycerophospholipid (GP) metabolism-in which APOA1 displayed a marked increase. Lipidomic profiling further revealed HS-induced disruptions in phosphatidylcholine (PC), phosphatidylethanolamine (PE), and cardiolipin (CL) metabolism. Additionally, blood-brain barrier integrity was compromised, as evidenced by increased perivascular IgG extravasation, reduced pericyte coverage, and decreased expression of tight junction proteins ZO-1 and Occludin. HS also triggered pronounced neuroinflammation, characterized by elevated levels of iNOS, GFAP, and pro-inflammatory cytokines (TNF-α, IL-1β, and IL-6). Notably, administration of D-4F, an APOA1 mimetic peptide, alleviated blood-brain barrier damage, reduced neuroinflammation, and preserved synaptic integrity, thereby suggesting a neuroprotective role for APOA1 in HS-induced hypothalamic dysfunction. These findings underscore the critical role of lipid metabolism in maintaining hypothalamic homeostasis under HS conditions and position APOA1 as a key regulator with potential therapeutic implications for mitigating HS-related neuroinflammatory and metabolic disturbances.

Blood-Brain Barrier

Intercellular adhesion molecule-1 in cerebrospinal fluid--the evaluation of blood-derived and brain-derived fractions in neurological diseases.

The soluble intercellular adhesion molecule-1 (sICAM-1) was measured in paired CSF and serum samples from 128 patients with different neurological diseases. The reference range of blood-derived sICAM-1 fractions in CSF was characterized with reference to the albumin CSF/serum quotients. The low mean concentrations of sICAM-1 of normal controls (n=33) in CSF (1.5 ng/ml; C.V.=40%) compared to serum (285.1 ng/ml; C.V.=32%) indicate that about 60% to 80% of sICAM-1 in normal lumbar CSF derives from blood. This calculation is based on the theoretically expected molecular size-dependent blood-CSF gradient between 300:1 to 250:1. In patients with non-inflammatory diseases (n=21) the sICAM-1 CSF/serum quotient increased non-linearly with increasing albumin CSF/serum quotient (blood-CSF barrier dysfunction) displaying the shape of a saturation-like curve in contrast to hyperbolic curves of other blood-derived proteins in CSF. This non-linear relation between sICAM-1 and albumin quotients does not allow a linear index evaluation reported in earlier studies. In bacterial meningitis (n=31) and viral meningoencephalitis (n=28) in addition to the increased blood-derived fraction, the brain-derived fraction of sICAM-1 in CSF was up to 12-fold higher than that in controls. The sICAM-1 CSF/serum quotients in MS (n=15) did not differ from non-inflammatory controls, i.e., there was no brain-dependent sICAM-1 fluctuation in CSF in contrast to the known fluctuations in blood. Earlier published reports on sICAM-1 have been controversial due to less sensitive assays and unsuitable linear evaluation concepts for blood-CSF barrier dysfunction.

Blood-Brain Barrier